Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Market Cap	10.51B
Revenue (ttm)	1.46B
Net Income (ttm)	447.34M
Shares Out	70.00M
EPS (ttm)	6.39
PE Ratio	23.50
Forward PE	21.13
Dividend	3.06 (2.08%)
Ex-Dividend Date	Jul 29, 2025

Volume	41,226
Average Volume	61,769
Open	147.00
Previous Close	147.10
Day's Range	146.40 - 151.20
52-Week Range	134.00 - 183.80
Beta	0.72
RSI	44.75
Earnings Date	Oct 23, 2025

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. The company offers human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 1,129
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2024, TADAWUL:4015's revenue was 1.32 billion, an increase of 19.77% compared to the previous year's 1.10 billion. Earnings were 356.52 million, an increase of 21.93%.